Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 2/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.30 |
| ▸ | NMT2 | O60551 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276860 | 1.00 | NQO1 (0.39) | NQO1GPR35LMNATDP1MEN1 | |
| SCHEMBL6271675 | 0.87 | NQO1 (0.43) | NQO1TDP1MEN1KMT2ACYP2A6 | |
| SCHEMBL6271677 | 0.87 | NQO1 (0.43) | NQO1TDP1MEN1KMT2ACYP2A6 | |
| SCHEMBL6276215 | 0.86 | NQO1 (0.43) | NQO1TDP1MEN1KMT2ACYP2A6 | |
| SCHEMBL6276208 | 0.86 | NQO1 (0.43) | NQO1TDP1MEN1KMT2ACYP2A6 | |
| SCHEMBL6270518 | 0.86 | NQO1 (0.48) | NQO1GPR35LMNATDP1MEN1 | |
| SCHEMBL6276932 | 0.85 | NQO1 (0.42) | NQO1GPR35LMNATDP1MEN1 | |
| SCHEMBL6273163 | 0.85 | POLM (0.35) | NQO1 | |
| SCHEMBL6273160 | 0.85 | POLM (0.35) | NQO1 | |
| SCHEMBL6275919 | 0.85 | CNR2 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273578-B1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK & CHEMICALS (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-6670391-B2 | For inhibiting both immediate and delayed type allergic reactions; side effect reduction | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1273578-A1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | HRH2, HRH1, HRH4 | NQO1 1320/4885GPR35 136/4885LMNA 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.